BMS releases Opdivo Phase III melanoma data

Bristol-Myers Squibb Co. (NYSE:BMY) said patients treated with Opdivo nivolumab as a first-line therapy for advanced melanoma had a one-year survival rate of 72.9%, compared to 42.1% in patients given dacarbazine (p<0.0001) in the Phase III CheckMate -066 trial.

In June, BMS stopped the trial early after Opdivo met the primary endpoint of improving overall survival (OS) vs. dacarbazine. The New England Journal of Medicine published results of the study on Sunday. ...